Medical Oncology

Mayo Clinic

Questions discussed in this category

How often do you assess for frailty in your clinical practice for patients with Multiple Myeloma and what tool do you use?

For example: eyeball test, simplified frailty assessment (Facon et al.), IMWG frailty score, ECOG only?

1 Answer available

Based on the DREAMM-7 and DREAMM-8 data, if approved again in the US, how would you incorporate belantamab mafadotin in your practice?

2 Answers available

Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?

1 Answer available

In the current myeloma landscape, do you make treatment decisions based on MRD results, either for MRD negativity or MRD resurgence?

2 Answers available

With the recent ODAC review of the commerically available CAR-T therapies in relapsed/refractory myeloma post 1-3 lines of therapy, what is your preferred regimen/therapy for first relapse, and which are the situations where you would absolutely consider CAR-T therapy at first relpase?

1 Answer available

Are there any circumstances where you recommend early institution of systemic therapy for patients with solitary plasmacytoma?

Specifically, do you offer closer follow-up for certain patients after local radiation?

3 Answers available

Do you recommend utilizing daratumumab in the maintenance phase after a quadruplet induction for transplant eligible multiple myeloma?

3 Answers available

With the CANOVA results in mind, would you continue using venetoclax in patients with multiple myeloma with t(11;14)?

1 Answer available

What is your approach to mitigating the infection risk with bispecific antibodies in multiple myeloma?

4 Answers available

How do you choose between the different recently approved Bispecifics Antibodies for Relapsed/Refractory Multiple Myeloma?

I.e. dosing regimen frequency, side effect profile, duration of follow up, etc.

3 Answers available

How do you manage IgM related peripheral neuropathy?

Do you utilize rituximab or any other specific management strategies?

2 Answers available

Do you recommend routinely getting periodic 24-hour urine monoclonal protein study for patients with active multiple myeloma?

If so, why?

4 Answers available

Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?

3 Answers available

Do you change treatment for confirmed biochemical progression in patients with otherwise secretory MM even if the M-spike is <0.5 g/dL?

3 Answers available

What is your approach for using anticoagulation/aspirin in patients with multiple myeloma?

2 Answers available

What is your preferred up-front treatment for transplant-eligible patients with primary (de novo) plasma cell leukemia?

2 Answers available

What are your takeaways from the GPRC5D-Targeted CAR-T trial (Mailankody et al. NEJM Sept 2022) and any key differences compared to the BCMA directed products?

1 Answer available

Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?

2 Answers available

Do you perform a periodic PET CT to screen for extramedullary disease in patients with MM who are in remission?

2 Answers available

Where does Elotuzumab-based combination therapy, specifically EPd, fit in your treatment paradigm for relapsed MM?

Does sequence matter?

1 Answer available

How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?

What factors (i.e. timing from transplant, dose, prior therapy) impact your decision?

1 Answer available

How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?

1 Answer available

What is your experience with using Frailty Index or other geriatric screening in making decisions for elderly patients with multiple myeloma?

Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?

2 Answers available

What is your treatment of choice for triple class refractory multiple myeloma?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

2 Answers available

Do you prefer carboplatin or cisplatin with etoposide for stage IV extra-pulmonary neuroendocrine carcinomas with a Ki-67 > 55%?

1 Answer available

What is your preferred maintenance strategy for high risk multiple myeloma?

2 Answers available

Would you consider PRRT re-treatment in a patient with a well differentiated NET previously treated with 4 cycles of PRRT?

2 Answers available

What is the role of liver transplant in NET?

3 Answers available

Papers discussed in this category

Am J Transplant, 2016 Jun 09

The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.

Transplantation, 2021 Apr 27

Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.

Surgery, 2017 Jun 16

Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.

JAMA Oncol, 2020 Apr 16

Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.

Eur J Nucl Med Mol Imaging, 2018 Sep 28

Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.

Br J Radiol, 2018 Mar 20

Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.

Eur J Nucl Med Mol Imaging, 2013 Sep 13

Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.

BMC Cancer, 2019 Aug 08

Salvage PRRT with Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.

Scand J Gastroenterol, 2021 Jan 20

Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study.

Int J Endocrinol, 2021 Jan 23

The Safety and Efficacy of the Repeated PRRT with [Y]Y/[Lu]Lu-DOTATATE in Patients with NET.

Cancer Treat Rev, 2020 Dec 22

Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.

The New England journal of medicine, 2012-05-10

Lenalidomide after stem-cell transplantation for multiple myeloma.

Nature communications, 2019-04-23

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Blood, 2012 Aug 13

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

J Clin Oncol, 2020 Apr 16

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

Blood,

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

The New England journal of medicine, 2017-04-06

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

The Lancet. Oncology, 2019-01

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Blood,

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

Blood, 2015-03-26

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

Clin Lymphoma Myeloma Leuk, 2019 Oct 09

Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.

JCO Oncol Pract, 2019 Nov 25

Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.

The New England journal of medicine, 2015-08-13

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

J Clin Oncol, 2022 Aug 12

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

Proc Natl Acad Sci U S A, 2019 Apr 15

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.

N Engl J Med,

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

N Engl J Med,

GPRC5D-Targeted CAR T Cells for Myeloma.

Clin Lymphoma Myeloma Leuk, 2020 Jul 29

Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.

Br J Haematol, 2021 Aug 15

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.

Blood, 2022 Dec 08

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.

Leukemia, 2019-03

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Leukemia, 2022 Feb 21

Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

Lancet, 2021 Jun 24

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med, 2023 Feb 10

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

Lancet Oncol, 2021 Dec 03

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

Lancet, 2021 Jun 04

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.

Br J Haematol, 2023 Jun 07

Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.

J Clin Oncol, 2021 Aug 13

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

The Lancet. Haematology, 2023 Sep 11

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

The Lancet. Oncology, 2021 Sep 13

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

The New England journal of medicine, 2019-05-30

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Blood, 2023 Nov 30

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.

Cancer, 2011-10-01

Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.

BMC Cancer, 2006 May 05

Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.

International journal of radiation oncology, biology, physics, 1998-07-15

Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.

International journal of radiation oncology, biology, physics, 2006-01-01

Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.

Blood, 2014 May 29

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma.

Blood, 2014 Jun 17

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.

International journal of radiation oncology, biology, physics, 2011 Jan 27

Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Dec 13

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

Lancet (London, England), 2019 Dec 10

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Blood, 2023 Jan 19

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

The New England journal of medicine, 2024 Jun 01

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine, 2024 Jun 02

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.

Leukemia & lymphoma, 2024 Apr 16

Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).

Medical Oncology

Mayo Clinic

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology